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Abstract
Background: FK506 binding protein 51 (FKBP51) is an Hsp90 co-chaperone and regulator of the glucocorticoid receptor,
and consequently of stress physiology. Clinical studies suggest a genetic link between FKBP51 and antidepressant response
in mood disorders; however, the underlying mechanisms remain elusive. The objective of this study was to elucidate the
role of FKBP51 in the actions of antidepressants, with a particular focus on pathways of autophagy.
Methods and Findings: Established cell lines, primary neural cells, human blood cells of healthy individuals and patients
with depression, and mice were treated with antidepressants. Mice were tested for several neuroendocrine and behavioral
parameters. Protein interactions and autophagic pathway activity were mainly evaluated by co-immunoprecipitation and
Western blots. We first show that the effects of acute antidepressant treatment on behavior are abolished in FKBP51
knockout (51KO) mice. Autophagic markers, such as the autophagy initiator Beclin1, were increased following acute
antidepressant treatment in brains from wild-type, but not 51KO, animals. FKBP51 binds to Beclin1, changes decisive protein
interactions and phosphorylation of Beclin1, and triggers autophagic pathways. Antidepressants and FKBP51 exhibited
synergistic effects on these pathways. Using chronic social defeat as a depression-relevant stress model in combination with
chronic paroxetine (PAR) treatment revealed that the stress response, as well as the effects of antidepressants on behavior
and autophagic markers, depends on FKBP51. In human blood cells of healthy individuals, FKBP51 levels correlated with the
potential of antidepressants to induce autophagic pathways. Importantly, the clinical antidepressant response of patients
with depression (n= 51) could be predicted by the antidepressant response of autophagic markers in patient-derived
peripheral blood lymphocytes cultivated and treated ex vivo (Beclin1/amitriptyline: r= 0.572, p= 0.003; Beclin1/PAR:
r= 0.569, p= 0.004; Beclin1/fluoxetine: r= 0.454, p= 0.026; pAkt/amitriptyline: r=20.416, p= 0.006; pAkt/PAR: r=20.355,
p= 0.021; LC3B-II/PAR: r= 0.453, p= 0.02), as well as by the lymphocytic expression levels of FKBP51 (r= 0.631, p,0.0001),
pAkt (r=20.515, p= 0.003), and Beclin1 (r= 0.521, p= 0.002) at admission. Limitations of the study include the use of male
mice only and the relatively low number of patients for protein analyses.
Conclusions: To our knowledge, these findings provide the first evidence for the molecular mechanism of FKBP51 in
priming autophagic pathways; this process is linked to the potency of at least some antidepressants. These newly
discovered functions of FKBP51 also provide novel predictive markers for treatment outcome, consistent with physiological
and potential clinical relevance.
Please see later in the article for the Editors’ Summary.
Citation: Gassen NC, Hartmann J, Zschocke J, Stepan J, Hafner K, et al. (2014) Association of FKBP51 with Priming of Autophagy Pathways and Mediation of
Antidepressant Treatment Response: Evidence in Cells, Mice, and Humans. PLoS Med 11(11): e1001755. doi:10.1371/journal.pmed.1001755
Academic Editor: Eric Nestler, Mount Sinai School of Medicine, United States of America
Received May 24, 2014; Accepted September 30, 2014; Published November 11, 2014
Copyright:  2014 Gassen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and its
Supporting Information files. The corresponding authors may be contacted at the indicated email addresses.
Funding: The study was financed by the Max Planck Institute of Psychiatry. The funders had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* Email: ncgassen@mpipsykl.mpg.de (NCG); theorein@mpipsykl.mpg.de (TR)
. NCG and JH contributed equally to this work.
" MVS and TR are joint senior authors on this work.
Abbreviations: 51KO, FKBP51 knockout; Akt1/2KO, Akt1/2 knockout; AMI, amitriptyline; ANOVA, analysis of variance; CoIP, co-immunoprecipitation; CSDS,
chronic social defeat stress; DEX, dexamethasone; FLX, fluoxetine; FST, forced swim test; HDRS, Hamilton Depression Rating Scale; MARS, Munich Antidepressant
Response Signature; MEF, mouse embryonic fibroblast; PAR, paroxetine; PBMC, peripheral blood mononuclear cell; SD, standard deviation.
PLOS Medicine | www.plosmedicine.org 1 November 2014 | Volume 11 | Issue 11 | e1001755
Introduction
Depression is the most common mental disorder, affecting an
estimated 350 million people worldwide [1]. While currently
available antidepressants show an overall favorable benefit/risk
balance, less than 50% of patients achieve sustained remission
following treatment, indicating a large inter-individual variability
in treatment efficacy and response [2]. The poor effectiveness of
antidepressants is at least partially due to the fact that the
mechanism of action of these drugs, which is responsible for their
clinical potency, is still largely unknown. As a consequence, it is
currently also not possible to predict treatment success in
individual patients, confining physicians and patients to lengthy
trial and error procedures with uncertain success.
FK506 binding protein 51 (FKBP51) is a regulator of the
glucocorticoid receptor, and consequently of the stress hormone
axis and stress physiology [3–7]. Human genetic studies have
suggested a link between FKBP51 and antidepressant response
rate [8–11]. Despite the intimate connection of stress physiology to
the pathophysiology and treatment of depression [12,13], the
mechanistic role of FKBP51 in antidepressant response has not
been elucidated.
Putative convergent molecular pathways common to both
FKBP51 and antidepressants might explain and substantiate the
suggested impact of FKBP51 on antidepressant response; the
modulation of these pathways by FKBP51 could influence their
reactivity to antidepressants. We analyzed whether these pathways
involve autophagic events based on reports stating that some
antidepressants alter at least the initial processes of autophagy
[14,15]. Given that FKBP51 can act via the central chaperone
Hsp90, which controls several kinases including the autophagy
regulators Akt and Beclin1 [16], intracellular autophagic events
appeared more likely than membrane targets of antidepressants to
be co-regulated by FKBP51.
Autophagy is a conserved cellular degradation process ensuring
continuous removal of damaged macromolecules and, thus, the
functional integrity of cells and tissues [17]. The predominant
form of autophagy involves the stepwise formation of an
autophagosome, which engulfs damaged cytosolic proteins or
organelles, and subsequent fusion of the autophagosome with a
lysosome to yield an autolysosome. This process is orchestrated by
a series of autophagy-related genes (Atg genes) and is regulated by
complex pathways that are partly under the control of the kinase
mTOR (mammalian target of rapamycin) [18]. Based on the
multitude of involved factors, autophagy is commonly assessed by
the determination of several autophagy executers. These include,
among others, the initiators Beclin1 and Vps34 (class III
phosphatidylinositol-3-kinase); Atg12 and LC3B-II (derived from
LC3B-I upon lipidation), which are involved in autophagosome
membrane expansion and vesicle formation; and LC3B-II in
association with mature autophagosomes. Very recently, the
mTOR-independent regulation of autophagy was reported: Akt-
dependent phosphorylation of Beclin1 shifts Beclin1’s action from
autophagy to apoptosis [19]. As the guardian of cellular
homeostasis, autophagy has been established as a pivotal process
in a range of (patho-)physiological conditions, including infectious
diseases, cancer, diabetes, and, more recently, neurotransmission
and neurodegeneration [20–23]. Indirect evidence reveals a
potential role of autophagy in depression; some antidepressants
change the autophagic flux and the expression of autophagy
markers [14,15,24–26]. Moreover, the induction of autophagy by
the mTOR inhibitor rapamycin was reported to exert antidepres-
sant-like effects in mice [27].
Assessing depression and the action of antidepressants in
animals is very challenging. Animals lack not only measurable
consciousness of self, self-reflection, and consideration of others,
but also hallmarks of the disorder such as depressed mood, guilt,
suicidality, or low self-esteem. Nonetheless, depression encom-
passes so-called endophenotypes that can be reproduced
independently and evaluated in animals, including physiologi-
cal, endocrine, and behavioral traits [28,29]. Chronic social
defeat stress (CSDS) [5,30,31] is a repeatedly validated
paradigm used to model specific endophenotypes of depression
[28]. To mimic the clinical treatment situation, chronic stress
paradigms can be combined with chronic antidepressant
treatment during the recovery period after chronic stress
exposure. In addition, the forced swim test (FST) is a simple
and widely used assay to measure the actions of antidepressants
in mice.
The objective of this study was to elucidate the role of FKBP51
in the actions of antidepressants using a broad interdisciplinary
approach combining methods from molecular and cell biology,
animal behavior, and clinical science. More specifically, we aimed
to test the hypothesis that the actions of FKBP51 and antidepres-
sants might synergize in regulating pathways of autophagy and
that this synergy might link to clinical treatment success.
Methods
Cell lines
Human embryonic kidney cells (HEK-293; ATCC, CRL-1573)
and mouse embryonic fibroblasts (MEFs) were maintained in
DMEM (Gibco) supplemented with 10% FCS and 100 units/ml
penicillin and streptomycin. FKBP51 knockout (51KO) and Akt1/
2 knockout (Akt1/2KO) MEFs (kind gift of Nissim Hay, University
of Illinois) have been described before [6,32].
Primary Cultures of Rat Primary Neurons and Astrocytes
Neocortical neurons were enriched from embryonic day 18 rat
brains, and enriched astroglial cultures were prepared from
postnatal day 1 rat pups (Sprague-Dawley, Charles River) and
handled as previously described [33,34].
FKBP51 Rescue in MEF 51KO cells
MEF cells were detached from the plate, and 26106 cells were
immediately resuspended in 100 ml of transfection buffer (50 mM
HEPES [pH 7.3], 90 mM NaCl, 5 mM KCl, 0.15 mM CaCl2)
[35]. A maximal amount of 5 mg of plasmid DNA was added to
the cell suspension, and electroporation was carried out using the
Amaxa Nucleofector system (program # T-020). Cells were
replated at a density of 105 cells/cm2 and further processed for
Western blot analysis.
Chemicals for Treatments
The following drugs were used: amitriptyline hydrochloride
(Sigma, A8404), bafilomycin A1 (Alfa Aeser, J61835), dexameth-
asone (Sigma, D1756), fluoxetine hydrochloride (Sigma, F132),
haloperidol (Sigma, H1512), ketamine hydrochloride (Sigma,
K2753), paroxetine hydrochloride hemihydrate (Sigma, P9623),
and scopolamine hydrobromide (Sigma, S1875).
Plasmids
Plasmids expressing FKBP51-FLAG, Akt1, Akt2, and LC3B
have been described previously [7,36–38]. The Akt1 and Akt2
plasmids were a kind gift from H. Lee, Moffitt Cancer Center.
FKBP51 Impacts Autophagy and Antidepressant Action
PLOS Medicine | www.plosmedicine.org 2 November 2014 | Volume 11 | Issue 11 | e1001755
Co-immunoprecipitation
Co-immunoprecipitations (CoIPs) of FLAG-tagged FKBP51/52
and FLAG-tagged FKBP51 with endogenous Akt were performed
in HEK-293 cells. 56106 cells were electroporated with 5 mg of
the respective expression plasmids using a GenePulser (Bio-Rad) at
350 V/700 mF in 400 ml of electroporation buffer (50 mM
K2HPO4/KH2PO4, 20 mM KAc [pH 7.35], 25 mM MgSO4).
After 3 d of cultivation in DMEM/10% FCS, cells were lysed in
CoIP buffer containing 20 mM Tris-HCl (pH 8.0), 100 mM
NaCl, 1 mM EDTA, and 0.5% Igepal, complemented with
protease inhibitor cocktail (Sigma, P2714). This was followed by
incubation on an overhead shaker for 20 min at 4uC. The lysate
was cleared by centrifugation, the protein concentration was
determined, and 1.2 mg of lysate was incubated with 2.5 mg of
FLAG antibody overnight at 4uC. 20 ml of BSA-blocked Protein G
Dynabeads (Invitrogen, 100-03D) were added to the lysate-
antibody mix, followed by 3 h of incubation at 4uC. The beads
were washed three times with PBS, and protein-antibody
complexes were eluted with 100 ml of 16 FLAG-peptide solution
(Sigma, 100–200 mg/ml, F3290) in CoIP buffer for 30 min at 4uC.
5–15 mg of the cell lysates or 2.5 ml of the immunoprecipitates was
separated by SDS-PAGE.
Western Blot Analysis
Protein extracts were obtained by lysing cells in 62.5 mM Tris,
2% SDS, and 10% sucrose, supplemented with protease (Sigma,
P2714) and phosphatase (Roche, 04906837001) inhibitor cocktail.
Samples were sonicated and heated at 95uC for 5 min. Proteins
were separated by SDS-PAGE and electro-transferred onto
nitrocellulose membranes. Blots were placed in Tris-buffered saline,
supplemented with 0.05% Tween (Sigma, P2287) and 5% non-fat
milk for 1 h at room temperature and then incubated with primary
antibody (diluted in TBS/0.05% Tween) overnight at 4uC. The
following primary antibodies were used: Beclin1 (1:1,000, Cell
Signaling, #3495), pBeclin1 (S234 and S295, both 1:1,000,
Phosphosolutions, #p117-234 and #p117-295), Atg12 (1:1,000,
Cell Signaling, #2010), LC3B-II/I (1:1,000, Cell Signaling,
#2775), FLAG (1:7,000, Rockland, 600-401-383), PI3K Class III
(Vps34, 1:1,000, Cell Signaling, #4263), FKBP51 (1:1,000, Bethyl,
A301-430A), Akt (1:1,000, Cell Signaling, #4691), pAkt (Ser473
and T308, both 1:1,000, Cell Signaling, #4058 and #9275), Actin
(1:5,000, Santa Cruz Biotechnology, sc-1616).
Subsequently, blots were washed and probed with the respective
horseradish-peroxidase- or fluorophore-conjugated secondary
antibody for 1 h at room temperature. The immuno-reactive
bands were visualized either using ECL detection reagent
(Millipore, WBKL0500) or directly by excitation of the respective
fluorophore. Recording of the band intensities was performed with
the ChemiDoc MP system from Bio-Rad and X-ray films.
Quantification of Protein Data
All protein data were normalized to Actin, which was detected
on the same blot in the same lane (multiplexing). In the case of Akt
phosphorylation, we built the ratio of pAktS473 to total Akt, as
indicated. We obtained very similar results leading to the same
conclusions when we normalized pAktS473 to Actin. In the case of
LC3B-II/I, we also provide the direct ratio of the two isoforms; we
also provide normalization of LC3B-II to Actin for a few
examples, yielding the same results.
Animals
All experiments were carried out in the animal facilities of the
Max Planck Institute of Psychiatry in Munich, Germany. The
51KO mouse line was previously generated [6] and fully
backcrossed (12 generations) to C57BL/6. Genotypes were
verified by PCR of tail DNA. Only male mice were used for the
experiment, obtained from heterozygous breeding pairs, to avoid
an influence of the menstrual cycle on the molecular and
behavioral outcomes. Animals were between 10 and 16 wk old
at the start of the experiment. Mice were held under standard
conditions (12L:12D light cycle, lights on at 08:00 am, temper-
ature 2362uC), were singly housed, and were acclimated to the
room for 1 wk before the beginning of the experiments. Male CD1
mice (16–18 wk of age) served as resident mice, which were held
under the conditions described above. They were allowed to
habituate to the social defeat cage for 2 wk before the experiment.
Food (Altromin, 1314) and tap water were available ad libitum.
Acute Animal Treatments and Behavioral Experiments
Acute paroxetine treatments. Male mice (age 10–16 wk)
were injected intraperitoneally with a single dose of either
paroxetine (PAR) (10 mg/kg) or saline vehicle. 45 min later, a
subgroup of mice (wild-type/vehicle, n=10; 51KO/vehicle, n=9;
wild-type/PAR, n=10; 51KO/PAR, n=10) was sacrificed.
Hippocampus and prefrontal cortex were extracted for protein
analysis. Another subgroup (wild-type/vehicle, n=8; 51KO/
vehicle, n=8; wild-type/PAR, n=9; 51KO/PAR, n=7) was
subjected to an FST (test duration 6 min) 45 min after the
injection. Another subgroup (wild-type, n=3; 51KO, n=4) was
sacrificed, and brain tissue was sampled for analysis of drug
concentrations.
Acute amitriptyline treatment. Male mice (age 10–16 wk)
were injected intraperitoneally with a single dose of either
amitriptyline (AMI) (10 mg/kg) or saline vehicle. 45 min later, a
subgroup of mice (wild-type/vehicle, n=10; 51KO/vehicle, n=9;
wild-type/AMI, n=9; 51KO/AMI, n=11) was subjected to an
FST. Another subgroup (wild-type, n=5; 51KO, n=5) was
sacrificed, and brain tissue and blood were sampled for analysis of
drug concentrations.
Acute treatment with haloperidol. C57BL/6 male mice
(age 10–16 wk) were injected intraperitoneally with a single dose
of haloperidol (0.2 mg/kg) or saline vehicle. 45 min later, the
animals were sacrificed, and the hippocampus and prefrontal
cortex were extracted for protein analysis.
Design of the Chronic Stress and Chronic PAR Treatment
Experiment
We analyzed the ability of 51KO mice to recover from CSDS
and the effects of chronic PAR treatment during a 3-wk recovery
period. Initially, wild-type and 51KO mice were split into 262
groups (control wild-type, control 51KO, defeat wild-type, defeat
51KO) and subjected to the chronic stress procedure described
below. After cessation of the stressor, groups were subdivided into
vehicle-treated and PAR-treated animals, resulting in eight groups
(vehicle: control wild-type, control 51KO, defeat wild-type, defeat
51KO; PAR: control wild-type, control 51KO, defeat wild-type,
defeat 51KO; n=7–13 per group). The treatment phase lasted
3 wk. The behavioral tests took place during the last week of the
PAR treatment. PAR (GlaxoSmithKline) was administered via
drinking water at a daily dose of ,20 mg/kg as described
previously [39].
Chronic Stress Procedure and Physiological Parameters
The CSDS paradigm lasted for 21 d and was conducted as
described previously [40]. Briefly, the experimental mice were
introduced into the home cage (45 cm625 cm) of a dominant
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resident mouse and defeated shortly after. When the defeat was
achieved, the animals were separated by a wire mesh, preventing
physical but allowing sensory contact for 24 h. Each day, stressed
animals were defeated by another unfamiliar dominant resident
mouse in order to exclude a repeated encounter throughout the
experiment. The daily defeat was performed between 11:00 and
16:00 h; varying starting times reduced the predictability of the
stressor and therefore minimized a potential habituation effect.
Experimental mice were always defeated by resident males during
the entire stress period. Control mice were housed in their home
cages during the course of the experiment. Both stress and control
animals were handled daily during the stress procedure; body
weight for all mice was assessed at the beginning of the
experiment, after the cessation of the stress period, and on the
day of killing. Animals that underwent the stress procedure were
subsequently single housed in standard cages.
Chronic Paroxetine Treatment
PAR (GlaxoSmithKline) was administered via drinking water as
described previously [39]. Briefly, the PAR solution was diluted in
tap water to a final concentration of 0.16 mg/ml. With average
water consumption of 5 ml/mouse/day, the daily dose of PAR
was ,20 mg/kg body weight. Fluid intake was monitored daily,
and the variation of fluid intake was found to be ,10% over the
course of the experiment.
Behavioral Analyses
The behavioral tests were carried out between 08:30 and 12:30
h in the same room in which the mice were housed. The testing
order was as follows: open-field test, social avoidance test, FST,
and acute stress response test. All tests were analyzed using an
automated videotracking system (Anymaze 4.20, Stoelting). All
animals underwent the same testing battery in the same order. To
minimize possible carryover effects of the different behavioral tests,
the sequence of tests was arranged from the least stressful to the
most stressful, with a minimum of 24 h between tests [41].
Open-field test. The open-field test was performed to
investigate locomotion differences. Testing was carried out in an
empty open-field arena (50 cm650 cm650 cm) made of gray
polyvinyl chloride (PVC), which was evenly illuminated with 15
Lux. The low illumination of the open-field arena was chosen to
specifically investigate locomotion behavior and not create an
aversive center region that may induce anxiety-related behavior.
Testing time was 10 min, and the main parameter of interest was
the total distance travelled.
Social avoidance test. The social avoidance test was
performed as described previously [42]. Briefly, animals were
allowed to explore the open-field arena for 2.5 min with an empty
wire mesh cage placed at one side of the apparatus. In a second
stage, the animals were confronted with an unfamiliar CD1
resident mouse in the wire mesh cage for another 2.5 min. The
ratio between the time in the interaction zone of the no-target trial
and the time in the interaction zone of the target trial serves as a
marker for disturbed social behavior associated with depressive
disorders. Animals that did not explore the interaction zone at all
were excluded from the analysis (excluded: wild-type control/
vehicle, 1; 51KO control/vehicle, 1; wild-type control/PAR, 2;
51KO control/PAR, 1; wild-type stress/vehicle, 1; 51KO stress/
vehicle, 1; wild-type stress/PAR, 1). The FST was performed one
day after the social avoidance test.
Forced swim test. In the FST, each mouse was put into a 2-l
glass beaker (diameter: 13 cm, height: 24 cm) filled with tap water
(2161uC) to a height of 15 cm, so that the mouse could not touch
the bottom with its hind paws or tail. Testing duration was 5 min.
Time spent immobile (floating) and time spent struggling was
scored by an experienced observer, blind to treatment or condition
of the animals.
Acute stress response test. The FST also served as an acute
stressor in order to determine the stress response by measuring
corticosterone plasma concentrations. After the FST, all mice were
towel-dried and placed into their home cage to recover from the
acute stressor. Blood samples were taken by tail cut [43] 30 min
(stress response) and 90 min (stress recovery) after the onset of the
FST. Samples were collected in 1.5-ml EDTA-coated microcen-
trifuge tubes (Kabe Labortechnik). All blood samples were kept on
ice and later centrifuged at 8,000 rpm at 4uC for 15 min. Plasma
was transferred to new, labeled tubes and stored at 220uC until
determination of corticosterone by radioimmunoassay (MP
Biomedicals; sensitivity 12.5 ng/ml).
Sampling Procedure
24 h after the last defeat, blood samples were taken by tail cuts,
in order to assess the plasma corticosterone levels immediately
after the chronic stress paradigm. 3 wk after the last defeat, thus
following 3 wk of treatment, all animals were killed by decapita-
tion following quick anesthesia by isoflurane at the end of the
experiment. Basal trunk blood samples were processed as
described above. Adrenal and thymus glands were removed,
dissected from fat, and weighed. Prefrontal cortex and hippocam-
pus were prepared for protein analysis.
The locations of brain regions were determined according to a
mouse brain atlas and were dissected using a mouse brain slicer
that allowed the dissection of discrete regions of the brain. The
prefrontal cortex dissections included prelimbic, infralimbic, and
orbitofrontal areas; the hippocampal dissections encompassed
dorsal and ventral subdivisions.
Determination of Drug Concentrations in Rodent Blood
and Brain
Tissue extraction and determination of drug concentrations by
high-performance liquid chromatography was performed as
described previously [44,45].
Analysis of GFP-LC3B in Astrocytes
26106 cells were transfected with 2 mg of GFP-LC3B-express-
ing plasmid or the respective cloning vector using the Amaxa
Nucleofector. Cells were grown and treated where indicated for
72 h and analyzed by fluorescence microscopy. At least 20 cells
were counted.
Human Samples
Healthy individuals. Protein-protein correlations were de-
termined in extracts from peripheral blood mononuclear cells
(PBMCs) from 21 healthy men (age 25.8 y, standard deviation
[SD] 2.7 y). Of these, 14 individuals received 1.5 mg of
dexamethasone (DEX), and protein expression changes in PBMCs
were determined 6 h later. FKBP51-dependent antidepressant
effects were evaluated in cultivated PBMCs from another 20
healthy men (age 34.8 y, SD 6.9 y).
Patients with depression. 51 consecutive participants (26
women, 25 men; age 49.0 y, SD 14.7 y) of the Munich
Antidepressant Response Signature (MARS) project were included
for protein expression analyses, PBMC cultivation, and ex vivo
treatment with antidepressants. The MARS project is an open-
label prospective clinical study conducted at the hospital of the
Max Planck Institute of Psychiatry and collaborating hospitals in
southern Bavaria and Switzerland to evaluate typical depression
FKBP51 Impacts Autophagy and Antidepressant Action
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courses under standard antidepressant treatment [46]. Patients
were diagnosed according to DSM-IV criteria [47]. Patients
suffered from major depressive disorder (single episode, n=13;
recurrent, n=32) or from a depressive episode within a bipolar
disorder (n=6). Depression severity was assessed using the 21-item
Hamilton Depression Rating Scale (HDRS) [48]; patients had an
average baseline score of 23.8 (SD 5.6), indicating severe
depression. Patients received antidepressant treatment in a
naturalistic study setting [46]. Antidepressant treatment outcome
was evaluated as percent change in HDRS score between baseline
and after 6 wk of treatment. The resulting variable was
approximately normally distributed with mean= 52.9 (SD 32.7)
with a Kolmogorov-Smirnov test suggesting no deviation from the
theoretical distribution (p=0.715). Fasting venous blood samples
for extraction of PBMCs were drawn from patients between 08:00
and 09:00 h within 5 d after admission. Further clinical
characteristics are summarized in Tables 1 and 2.
Preparation and Treatment of Human Peripheral Blood
Mononuclear Cells
Blood of healthy men and of patients with depression was
collected via venipuncture, diluted with PBS, carefully loaded on
Biocoll solution (BioChrom, L6113), and centrifuged at 800 g for
20 min (brakeless running down). PBMCs were enriched by
selecting the interphase of the Biocoll gradient. PBMCs of the
interphase were washed two times with ice-cold PBS. PBMCs were
resuspended in RPMI and plated at 46105 cells/cm2. After
recovery for 6 h, cells were treated with 888 nM (120 ng/ml)
AMI, 1,695 nM (500 ng/ml) fluoxetine (FLX), or 365 nM
(120 ng/ml) PAR. Concentrations had been chosen to match
therapeutic concentrations in the serum according to the
consensus guidelines for therapeutic drug monitoring in psychiatry
[49].
Ethics Statement
Approval for the MARS project was received from the ethics
committee in charge (submission number 318/00, ethics commit-
tee of the Medical Faculty at Ludwig Maximilian University of
Munich, Germany), and participants gave oral and written
consent before study inclusion.
The animal experiments were carried out in accordance with
European Communities’ Council Directive 2010/63/EU. All
efforts were made to minimize animal suffering during the
experiments; all experiments were based on the 3R principles:
reduction, refinement, replacement. The protocols were approved
by the Committee for the Care and Use of Laboratory Animals of
the Government of Upper Bavaria, Germany.
Statistical Analysis
The data presented were analyzed using the commercially
available software SPSS 16.0. When two groups were compared,
the Student’s t-test was applied. For three or more group
comparisons, one-way, two-way, or three-way analysis of
variance (ANOVA) was performed, followed by Tukey’s post-
hoc test, as appropriate. All ANOVA F- and p-values are
reported in Table S1; significant results of the contrast tests are
indicated by asterisks in the figures. Protein-protein associations
were analyzed using Pearson correlations. In the clinical sample,
associations between human protein expression and antidepres-
sant treatment outcome as well as protein-protein interactions
were evaluated with Pearson correlations after correction for the
effects of age and gender (partial correlation). p,0.05 was
considered significant.
Results
FKBP51-Dependent Effects of Paroxetine and
Amitriptyline on Behavior in FKBP51 Knockout Mice and
Identification of FKBP51-Directed Pathways of
Autophagy
To assess whether FKBP51 modulates antidepressant response
in mice, we treated wild-type and 51KO mice with an acute dose
(10 mg/kg, as described previously [50–52]) of the antidepressants
PAR or AMI. After 45 min, we subjected the mice to the FST as a
well-established test for animals’ response to antidepressants. PAR-
treated wild-type mice spent less time floating (immobility)
compared to vehicle-treated wild-type mice (p=0.001), thus
exhibiting the expected response to antidepressants. In contrast,
the effect of PAR was significantly less pronounced in 51KO mice
(wild-type/PAR versus 51KO/PAR, p=0.001) (Figure 1A). Sim-
ilarly, PAR treatment led to an increase in the time spent
struggling in wild-type mice (p=0.001). This effect of PAR was
significantly attenuated in 51KO mice (wild-type/PAR versus
51KO/PAR, p=0.001) (Figure 1A). Treatment with AMI pro-
duced similar results, i.e., deletion of FKBP51 entailed loss of
antidepressant effects on struggling and floating times (Figure 1B).
To evaluate molecular effects of antidepressants that may
depend on FKBP51 and parallel the behavioral phenotype, we
analyzed autophagy markers in protein extracts from the
hippocampus and prefrontal cortex after antidepressant injection
(10 mg/kg). In wild-type mice, PAR treatment increased the levels
of Beclin1 (hippocampus, p=0.005; prefrontal cortex, p=0.001),
Atg12 (hippocampus, p=0.001; prefrontal cortex, p=0.004), and
Vps34 (hippocampus, p=0.001; prefrontal cortex, p=0.001);
increased the ratio of LC3B-II/I (hippocampus, p=0.005;
prefrontal cortex, p=0.001); and evoked dephosphorylation of
the kinase Akt (hippocampus, p=0.002; prefrontal cortex,
p=0.001; phosphorylation at S473 in Akt1 represents the
activated form [pAktS473]); in contrast, 51KO mice showed no
alterations in protein levels of autophagy markers or pAktS473 in
either brain region after PAR treatment (Figures 1C–1G and
S1A). Similar results were obtained with AMI-treated mice, where
the antidepressant effects on markers of autophagy were largely
abolished in 51KO mice (Figures 1H–1K and S1B).
We considered the possibility that FKBP51 may act as an
inhibitor of the blood-brain barrier, and its deletion may thus lead
to a more efficient removal of antidepressants from the brain. We
determined the levels of PAR, AMI, and nortriptyline—an active
metabolite of AMI—in the blood and in the brain 45 min after
injection of PAR or AMI in wild-type and 51KO mice. No
indications of enhanced blood-brain barrier function could be
detected for any of the drugs (Figure 1L).
The results in 51KO mice suggest a role of FKBP51 in
autophagic events, which we further evaluated using biochemical
and cell biological methods. Because FKBP51 has been reported
to interact with Akt [53], which in turn regulates Beclin1 [19], we
initially tested whether FKBP51 interacts with Beclin1. FLAG-
tagged FKBP51 was expressed in HEK cells to assess its
interaction with the autophagy initiator Beclin1 by CoIP. FKBP51
displayed binding to Beclin1 (Figure 2A), in addition to the
previously reported interaction with Akt and the phosphatase
PHLPP [53].
A direct effect of Akt on Beclin1 has been identified as an
important mechanism blocking autophagy [19]. Thus, we next
tested whether FKBP51 affects the interaction between Akt and
Beclin1. Increasing the levels of FKBP51 by transient transfection
in HEK cells led to higher overall levels of Beclin1 (p=0.031;
Figures 2B and S2A) and to higher amounts of Akt co-
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precipitating with Beclin1 (p=0.036, normalized to precipitated
Beclin1; Figures 2C and S2B). In addition, FKBP51 lowered the
amounts of pAktS473 interacting with Beclin1 (p=0.043; Figur-
es 2C and S2B). Furthermore, FKBP51 increased the levels of
autophagy promoting dephosphorylated Beclin1 (p=0.011 for
S295; Figures 2C and S2B). The overall level of pAktT308
(conferring basal activity) was unchanged upon expression of
FKBP51, while the pAktS473 levels were reduced (p=0.020;
Figures 2B and S2A). This is in line with previous findings and has
been explained by the recruitment of the phosphatase PHLPP to
Akt [53]. Together, these findings support a model in which
FKBP51 acts 2-fold on Beclin1: first, by increasing the overall
Beclin1 levels and, second, by recruiting the inactive (dephos-
phorylated by PHLPP) form of AktS473 to Beclin1.
To evaluate whether FKBP51’s effects on Beclin1 are accom-
panied by alterations of other autophagy markers, we compared
51KO and wild-type MEFs. MEFs lacking FKBP51 displayed
reduced levels of Beclin1 and decreased levels of two other
autophagy proteins, LC3B-II/I and Atg12 (Figure 2D). Consistent
with the reduced levels of pAktS473 observed in HEK cells upon
ectopic expression of FKBP51 (Figures 2B and S2A), deletion of
FKBP51 in MEF cells resulted in higher levels of pAktS473
(p=0.001; Figure 2D). These effects of FKBP51 gene deletion
were attenuated by ectopic expression of FKBP51 in 51KO MEFs
(Figure 2D).
To test whether the impact of FKBP51 on protein interaction
between Beclin1 and Akt characterized in HEK cells (Figure 2B) is
also relevant to the mouse brain, we performed immunoprecip-
itation using protein extracts of the brain from wild-type and
51KO mice. Abolition of FKBP51 significantly reduced the
interaction between Akt and Beclin1 (p=0.011; Figure 2E).
While LC3B-II/I in itself is often used as a marker of
autophagy, its increase per se is not proof of functional autophagic
flux; in contrast, this increase may also indicate a block of
autophagic flux [54]. Therefore, to test the possibility that
FKBP51 may actually block autophagy at terminal stages, we
analyzed the effect of FKBP51 in primary astrocytes as a model of
neural cells in the presence and absence of bafilomycin A1, which
is a V-ATPase inhibitor causing an increase in lysosomal pH,
thereby blocking autophagic flux [54]. Ectopic expression of
FKBP51 also increased LC3B-II/I in the presence of bafilomycin
A1 (p=0.003; Figures 2F and S3), indicating that FKBP51 not
only leads to increases in early markers of autophagy, but also
increases, at least partially, autophagic flux [54]. Together, the
data corroborate a stimulatory role of FKBP51 on autophagy.
Given that FKBP51 acts on a variety of intracellular proteins,
we used Akt1/2KO MEFs to test whether FKBP51’s impact on
pAktS473 was required for its influence on autophagic markers. In
wild-type MEFs, transfection of FKBP51 increased the levels of
the autophagy markers Beclin1 (p=0.001) and LC3B-II/I
(p=0.001; Figure 2G). These effects of FKBP51 were not
observed in Akt1/2KO MEFs, but were restored after reintro-
ducing Akt1 and Akt2 into Akt1/2KO MEFs by transient
transfection (Figure 2G). Thus, the impact of FKBP51 on
autophagy markers requires Akt1 and/or Akt2.
Cellular Effects of Antidepressants on Autophagic
Markers Depend on FKBP51
To determine potential effects of antidepressants on the
FKBP51-directed autophagic events characterized above, we
tested whether PAR, AMI, or FLX impacted on FKBP51
heterocomplexes in HEK cells. Each antidepressant was used at
10 mM, the concentration that proved sufficient for induction of
autophagy markers in cell culture (Figure S4 and [14]). Treatment
with PAR increased the amount of Akt and Beclin1 co-
precipitating with FKBP51 (Akt, p=0.014; Beclin1, p=0.012;
Figures 3A and S5A). Similar effects were observed with AMI,
while FLX showed no effect (Figure S5A).
Both a decrease and an increase of pAktS473 induced by
antidepressants have been reported to date [55,56]. To test the
impact of antidepressants on pAktS473 in neural cells, we used rat
primary astrocytes. PAR led to decreased levels of pAktS473 (p,
0.001; Figures 3B and S5B); however, the decrease was not
significant for AMI and FLX (Figures S5B and S5C). The
antidepressant effect was stronger when FKBP51 was transfected
into astrocytes (significant for PAR).
The importance of FKBP51 for antidepressant effects on
components of the autophagy pathway was further evaluated in
51KO and Akt1/2KO MEFs. PAR, AMI, and FLX reduced
pAktS473 in wild-type MEFs, but not in 51KO MEFs; ectopic
expression of FKBP51 in 51KO MEFs restored the effect of
antidepressants on pAktS473 (Figures 3C, S5D, and S5E). The
autophagy marker LC3B-II/I was elevated upon antidepressant
treatment in wild-type MEF cells (Figures 3D, S5D, and S5F), as
reported previously for astrocytes [14]. This antidepressant effect
was blunted in 51KO MEFs, and was restored when FKBP51 was
Table 1. Demographic and clinical characteristics of the MARS patient sample.
Characteristic MARS Patients (n=51)
Gender, percent female 26 (51%)
Age, mean ± SD 49.0614.7 y
Diagnoses, number (percent)
Major depressive disorder— single episode 13 (25%)
Major depressive disorder—recurrent 32 (63%)
Bipolar depression 6 (12%)
Duration of current episode, MD (IQR) 19 (8; 52) wk; range: 2–450 wk
Number of previous episodes, MD (IQR) 1 (0; 3) episodes; range: 0–20
HDRS at admission, mean ± SD 23.865.6
Because of a non-normal distribution of duration of the current episode and number of previous episodes, the median, the interquartile range, and the total range are
reported for these two variables.
IQR, interquartile range (25% and 75% percentiles); MD, median.
doi:10.1371/journal.pmed.1001755.t001
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ectopically expressed in these cells. In Akt1/2KO MEFs,
antidepressant exposure did not induce changes in the ratio of
LC3B-II/I (Figure S6A and S6B). When Akt1 and Akt2 were
reintroduced by ectopic expression, the effects of antidepressants
re-emerged.
The shift of LC3B from cytosolic to autophagosomal compart-
ments is also a major hallmark of autophagy. The influence of
FKBP51 on the capability of antidepressants to change the
distribution of recombinant GFP-LC3B was monitored in primary
cortical astrocytes. Ectopically expressed FKBP51 enhanced
antidepressant-induced clustering of GFP-LC3B (p=0.001; Fig-
ures 3E, 3F, S6C, and S6D). In the absence of antidepressants,
FKBP51 triggered the formation of GFP-LC3B-positive puncta to
a lesser extent. Further, FKBP51 enhanced the ability of
antidepressants to induce conversion from LC3B-I to LC3B-II
and to elevate Beclin1 and Atg12 levels in primary astrocytes
(Figures 3G–3I, S5B, and S6E; p=0.001 for Beclin1 and PAR,
p=0.001 for LC3B-II/I and PAR, p=0.010 for Atg12 and PAR).
Collectively, these data support the conclusion that the cellular
antidepressant effects on autophagy pathways depend on FKBP51.
Although antidepressant exposure in cell culture is typically
applied for 1–4 d, we hypothesized that short-term treatment for
45 min would also elicit autophagic makers, mirroring the 45-min
acute treatment duration design in mice. Treatment of primary
astrocytes revealed that PAR, AMI, and partly also FLX evoked a
response of the autophagic markers Beclin1, Atg12, pAkt, and
LC3B-II/I after 45 min of treatment (Figure S7).
We also tested whether the antidepressants actually affected
autophagic flux under our experimental conditions. We found that
antidepressants increased LC3B-II/I in the presence of bafilomy-
cin A1 (p=0.001 for both PAR and AMI; Figures 3J and S8),
indicating at least some increase in autophagic flux [54]. The
influence of FKBP51 on antidepressant effects was also evaluated
in rat primary neurons. We found that FKBP51 and PAR also
synergize in neurons to enhance Beclin1 protein levels (Figure S9).
The dissociative anesthetic ketamine and the tropane alkaloid
scopolamine have been proposed as fast-acting antidepressants
[57,58]. In addition, they have been linked to the activity of the
kinase mTOR, which is also a known inhibitor of autophagy.
Therefore, we tested the potential effect of ketamine and
scopolamine on autophagy markers, and additionally included
the neuroleptic haloperidol as a non-antidepressant. Mice (n=6)
were intraperitoneally injected with drug or vehicle and sacrificed
45 min later for protein analysis of hippocampus and prefrontal
cortex. None of the drugs induced markers of autophagy;
scopolamine somewhat reduced the levels of Beclin1 (p=0.005
at 1 mM, p=0.001 at 3 mM; Figure S10), consistent with its
reported activation of mTOR [58].
The Effects of Chronic Paroxetine Treatment on Behavior
and Autophagic Pathways in Mice Depend on FKBP51
To more closely mimic the clinical situation, we also assessed
the effect of FKBP51 deletion in mice after chronic PAR or
vehicle treatment; in addition, we applied CSDS, as it is
suggested to model some endophenotypes of depression [28].
Mice were subjected to 3 wk of CSDS, followed by 3 wk of PAR
treatment, with behavioral tests during the last week (Fig-
ure 4A).
The results determined from body weight, adrenal weight,
thymus weight, and corticosterone levels show that FKBP51
shapes the long-lasting physiological and neuroendocrine effects of
CSDS (Figures 4 and S11), consistent with our previous findings
on the immediate effects of FKBP51 on chronic stress [5].
On the day of sacrifice (day 43, after 3 wk of treatment), we
found a main genotype effect (p,0.0001) (for statistical details see
Table S1) and a condition6treatment interaction (p=0.074) for
body weight (Figure 4C). In order to isolate genotype-dependent
stress and treatment effects, we normalized the data to either
unstressed controls or vehicle treatment. First, we normalized all
stressed groups by assessing the difference in body weight
compared to their corresponding unstressed control group of the
same genotype and treatment. We found a significant treatment
effect (p=0.024): stress-induced increase in body weight was
significantly more pronounced in vehicle-treated mice than in
PAR-treated mice (Figure 4D, left). To isolate stress effects as well
as genotype-dependent treatment effects, we then normalized all
PAR-treated groups by assessing the difference in body weight
compared to their corresponding vehicle treated control groups of
the same genotype and condition. Two-way ANOVA revealed a
significant condition (p=0.02) and genotype effect (p=0.042).
PAR-induced body weight increase was significantly enhanced in
mice under basal conditions compared to stressed animals.
Interestingly, 51KO mice were significantly less affected by
PAR-induced body weight increase than wild-type mice (Fig-
ure 4D, right).
To assess the behavioral effects of FKBP51 deletion on the
actions of CSDS and chronic PAR treatment we used a social
interaction paradigm in addition to the FST. Moreover, we
analyzed general locomotion in an open-field test to control for
potential confounding effects. The total distance traveled in the
open-field test did not differ between genotype, condition, or
treatment groups (Figure 5A). In the social avoidance test,
Table 2. Regression model predicting cortisol response in the first and second dexamethasone/corticotropin releasing hormone
test (in terms of total area under the curve) using gender, age, dexamethasone-suppressed baseline cortisol, and baseline copeptin
as predictor variables.
Variable First DEX/CRH Test (n=122) Second DEX/CRH Test (n=120)
Beta p-Value Beta p-Value
Gender 0.11 0.054 0.14 0.025
Age 20.03 0.615 20.04 0.546
Baseline cortisol 0.78 ,0.001 0.61 ,0.001
Baseline copeptin 0.15 0.008 0.31 ,0.001
Baseline values have been collected under the suppressive effects of DEX, but prior to stimulation with 100 mg of human corticotropin releasing hormone. Values with
p,0.05 are in bold.
CRH, corticotropin releasing hormone.
doi:10.1371/journal.pmed.1001755.t002
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Figure 1. FKBP51 is required for acute effects of paroxetine and amitriptyline on behavior and autophagic pathways. (A and B) Two
batches of 51KO and wild-type mice were treated with PAR (10 mg/kg) or vehicle (A), or with AMI (10 mg/kg) or vehicle (B) and subjected to the FST
(n=7–9 per group). Graphs show the times of immobility and struggling. (C–G) 51KO and wild-type mice were treated with PAR (10 mg/kg) or vehicle
and sacrificed 45 min later. The levels of the indicated proteins were determined in extracts of the hippocampus and the prefrontal cortex from 9–11
animals per group. (H–K) Similar experiments were performed with AMI (10 mg/kg) instead of PAR. (L) Deletion of FKBP51 does not change blood-
brain barrier function. 51KO and wild-type mice were treated with AMI (10 mg/kg, n= 5 for both wild-type and 51KO mice) or PAR (10 mg/kg, n=4
for wild-type mice, n= 3 for 51KO mice) and sacrificed 45 min later. Levels of PAR, AMI, and the active AMI metabolite nortriptyline (NOR) were
determined in blood and brain. Graphs display the ratio of the concentration in the brain (nanograms of drug per gram of brain tissue) and the
concentrations in the plasma (nanograms of drug per milliliter of plasma). *p,0.05; **p,0.01; ***p,0.001. Statistical parameters in Table S1.
doi:10.1371/journal.pmed.1001755.g001
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deletion of FKBP51 resulted in loss of effects by CSDS and by
chronic PAR treatment. Three-way ANOVA revealed a main
treatment effect (p=0.016), a genotype6condition interaction
(p=0.077), and a genotype6treatment interaction (p=0.043)
(Figure 5B). To isolate treatment effects and genotype-dependent
stress effects, we normalized all stressed groups by assessing the
difference in the social interaction ratio compared to their
corresponding unstressed control group of the same genotype
and treatment. We found that CSDS significantly reduced social
behavior in wild-type mice, but not in 51KO mice (p=0.003)
(Figure 5C). To isolate stress effects and genotype-dependent
treatment effects, we normalized all PAR-treated groups by
assessing the difference in the social interaction ratio compared to
their corresponding vehicle-treated control group of the same
genotype and condition. PAR significantly enhanced social
behavior in wild-type mice, but not in 51KO mice, both in
CSDS-exposed and control animals (p=0.024) (Figure 5D). In the
FST, chronic PAR treatment was significantly less effective in
enhancing struggling and reducing floating in FKBP51-deleted
mice compared to wild-type mice. We observed a genotype6
Figure 2. FKBP51 directs autophagic pathways. (A) FKBP51 interacts with Beclin1, Akt, and PHLPP. HEK cells were transfected with vector
control (lanes 1 and 3) or a FLAG-tagged FKBP51-expressing plasmid (lanes 2 and 4) and lysed 72 h later. After immunoprecipitation (IP) of protein
complexes using a FLAG antibody, input (lanes 1 and 2) and (co)precipitated (lanes 3 and 4) proteins were visualized by Western blotting. (B) Change
of total Beclin1, pAktS473, and pAktT308 upon expression of FKBP51. Representative Western blots on the right. FKBP51 was detected by an antibody
directed against its FLAG tag. (C) FKBP51 interacts preferentially with dephosphorylated Akt and promotes Akt dephosphorylation. Graphs display
quantification of pBeclin1 (S234 and S295) and Beclin1-Akt/pAktS473 interaction after Beclin1 immunoprecipitation from HEK cells transfected with
FKBP51/52 (details in Figure S2). (D) Comparison of the endogenous protein levels of effects of Beclin1, LC3B-II/I, Atg12, and pAktS473 levels in wild-
type MEFs, 51KO MEFs, and 51KO MEFs transfected with FKBP51 or vector control. Graphs show the relative expression, with the levels of wild-type
cells transfected with vector control set to 1 (dashed line). Representative Western blots on the right. (E) Quantification of Beclin1-Akt interaction after
Beclin1 immunoprecipitation in brain extracts from wild-type and 51KO mice. Graph represents the results from five independent experiments.
Representative Western blots on the right. (F) FKBP51 enhances autophagic flux. Cortical rat astrocytes were transfected with FKBP51 or vector and
treated with bafilomycin A1 (BafA1) as indicated, and the levels of LCB3-II/I were determined. (G) Cellular effects of FKBP51 on autophagic markers
require Akt1 and/or Akt2. The protein levels of Beclin1 and LC3B-II/I were evaluated in wild-type MEFs, Akt1/2KO MEFs, and Akt1/2KO MEFs
transfected with Akt1- and Akt2-expressing plasmids. Graphs display the relative expression of three different experiments; expression in wild-type
vector-transfected MEFs was set to 1 (dashed line). Representative Western blots on the right. *p,0.05; **p,0.01; ***p,0.001. See Table S1 for
statistical details. ect., ectopic; genot., genotype; KO, 51KO; WT, wild-type.
doi:10.1371/journal.pmed.1001755.g002
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treatment interaction for the parameters struggling (p=0.056) and
floating (p=0.032) (Figure 5E and 5F). To isolate stress effects
and genotype-dependent treatment effects, we normalized all
PAR-treated groups by assessing the difference in struggling and
floating compared to their corresponding vehicle-treated control
group of the same genotype and condition. In both parameters,
51KO mice were significantly less affected by PAR treatment than
wild-type mice, independent of condition (struggling: p=0.017;
floating: p=0.002) (Figure 5G and 5H).
Analysis of the protein parameters of autophagic pathways in
the brains of mice exposed to CSDS and chronic PAR revealed a
main genotype effect (p=0.037), a main condition effect
(p=0.013), and a genotype6treatment interaction (p=0.049) for
Beclin1 (Figure 5I) and for Atg12 (Figure 5K). PAR increased
Beclin1 (p=0.016) (Figure 5J) and Atg12 (p=0.008) (Figure 5L) in
wild-type mice, but not in 51KO mice. For pAkt, a main genotype
effect (p=0.017), a main treatment effect (p=0.008), and
genotype6treatment interaction (p=0.005) were observed
Figure 3. FKBP51 enhances cellular effects of antidepressants. (A) The interaction of FKBP51 with Beclin1 and Akt in HEK cells in the presence
or absence of PAR (10 mM, 72 h) was analyzed by CoIP. (B) Primary rat cortical astrocytes were transfected with vector control or FKBP51 and treated
with PAR (10 mM) for 72 h, and the pAktS473/Akt ratio was determined. (C and D) Wild-type MEFs, 51KO MEFs, and 51KO MEFs transfected with
FKBP51 or vector control were treated with PAR (10 mM) for 72 h; pAktS473/Akt (C) and LC3B-II/I (D) ratios were determined. Protein levels in untreated
wild-type MEFs were set to 1 (dashed line). (E) Primary astrocytes were cotransfected with GFP-LC3B and vector control or FKBP51, and treated with
PAR (10 mM) for 72 h. The number of GFP-LC3B-positive puncta/cell was determined in 15–25 randomly selected cells for each condition. (F)
Representative fluorescence images of (E). (G–I) Primary astrocytes were transfected with vector control or FKBP51, and treated as in (B); Beclin1,
LC3B-II/I, and Atg12 levels were determined. Protein levels of untreated vector-transfected cells were set to 1 (dashed line). (J) Antidepressants
enhance autophagic flux. Rat cortical astrocytes were incubated with the drugs as indicated for 2 h, and the levels of LC3B-I, LC3B-II, and Actin were
determined in protein extracts by Western blotting. The graph displays the median ratio of LC3B-II/I from three independent experiments. *p,0.05;
**p,0.01; ***p,0.001. Statistical parameters in Table S1. BafA1, bafilomycin A1; ect., ectopic; genot., genotype; IP, immunoprecipitation; KO, 51KO;
RAP, rapamycin; WT, wild-type.
doi:10.1371/journal.pmed.1001755.g003
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(Figure 5M). CSDS and PAR elicited an effect (p=0.049) on pAkt
in wild-type mice, but not in 51KO mice (Figure 5N and 5O). For
LC3B-II/I, a main treatment effect (p=0.030) and genotype6
condition interaction (p=0.069) were found (Figure 5P). CSDS
and PAR increased LC3B-II/I in wild-type mice, but not in 51KO
mice (CSDS: p=0.013; PAR: p=0.080) (Figure 5Q and 5R).
The data from CSDS and chronic PAR treatment support the
conclusion that FKBP51 also impacts on the effects of chronic
PAR treatment.
Human Studies
To translate the findings derived from cellular and animal
experiments to humans, we used PBMCs from different cohorts.
PBMCs from 21 healthy men (age 25.8 y, SD 2.7 y) were analyzed
for protein-protein correlations. Of these healthy individuals, 14
received the synthetic glucocorticoid DEX to evaluate the link of
FKBP51-directed pathways to stress. PBMCs from another 20
healthy men (age 34.8 y, SD 6.9 y) were cultivated to assess
FKBP51-dependent antidepressant effects. The patient cohort
Figure 4. Deletion of FKBP51 diminishes the physiological effects of chronic stress and chronic PAR treatment. (A) Time course of the
experiment. Body weight was assessed on day 1, day 22, and day 43. Basal corticosterone was measured on day 22 and day 43. The behavioral testing
(open-field test, social avoidance test, and FST) and the stress response test (corticosterone samples 30 min and 90 after the FST) were performed in
the last week of the treatment phase. (B–G) Weights of body, thymus, and adrenal glands. When the three-way ANOVA indicated an interaction effect
(p,0.1), genotype-dependent stress and treatment effects were isolated by normalizing the data to either unstressed controls or vehicle treatment.
(B) Body weight was significantly reduced in 51KO mice before the start of the first defeat. At day 22, significant main effects for condition and
genotype were observed: CSDS induced an increase of body weight in both wild-type and 51KO mice, while 51KO mice still showed reduced body
weight compared to wild-type mice. (C and D) Stress-induced body weight increase was still present after 3 wk of recovery. PAR-induced increase of
body weight was most pronounced under control conditions. 51KO mice were less affected by PAR-induced body weight increase. (E and F) 51KO
mice showed overall reduced adrenal gland weight compared to wild-type mice. Adrenal gland weight was significantly increased in stressed
animals. The stress effect was less pronounced in 51KO mice than in wild-type animals. PAR led to adrenal gland enlargement in wild-type mice and
reduction in 51KO mice. (G) Thymus size was significantly reduced following CSDS. 51KO mice demonstrated significantly lower thymus weight than
wild-type mice. Asterisks indicate significant result for planned contrast test for main genotype effect (#), main treatment effect ($), or main
condition effect (+): *p,0.05; **p,0.01; ***p,0.001. See Table S1 for all statistical parameters. BW, body weight; WT, wild type.
doi:10.1371/journal.pmed.1001755.g004
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consisted of 51 consecutive participants (26 women, 25 men; age
49.0 y, SD 14.7 y) of the MARS project [46]. Depression severity
was assessed by using the 21-item HDRS [48]; patients had an
average baseline score of 23.8 (SD 5.6), indicating severe
depression. More details of the clinical sample are provided in
Table 1.
Effects of Antidepressants and of Dexamethasone in
Blood Cells of Healthy Individuals Depend on FKBP51
Determination of basal FKBP51 expression in PBMCs derived
from healthy men revealed marked variations (Figures 6 and
S12A). The FKBP51 expression level was positively correlated
with the expression of Beclin1 (Pearson correlation coefficient
r=0.726, p=0.0003) and Atg12 (Pearson correlation coefficient
r=0.452, p=0.046), and negatively correlated with the phos-
phorylation status of AktS473 (Pearson correlation coefficient r=2
0.537, p=0.015); LC3B-II/I displayed a non-significant correla-
tion with FKBP51 protein levels (Pearson correlation coefficient
r=0.423, p=0.056) (Figure 6).
Since FKBP51 is a stress-responsive gene [3,59] and
glucocorticoids have been shown to induce autophagy [60],
FKBP51 might also link stress to autophagy. We determined
the expression of Beclin1 and FKBP51 in PBMCs from healthy
men before and 6 h after administration of the synthetic
glucocorticoid DEX (1.5 mg). There was a significant corre-
lation between the induction of FKBP51 and the increase in
Beclin1 expression (Pearson correlation coefficient r= 0.737,
p= 0.002; Figures 7A and S12B), and a non-significant
correlation between the induction of FKBP51 and the
dephosphorylation of pAktS473 (Pearson correlation coefficient
r=20.497, p= 0.07; Figures 7B and S12B). In an animal
model, DEX affected levels of Beclin1, Vps34, and pAktS473 in
cortical astrocytes from wild-type mice, but not from 51KO
mice (Figure S12C–S12F).
PBMCs from healthy men were also cultivated ex vivo and
treated with AMI, FLX, or PAR for 48 h. To more closely mimic
the clinically relevant in vivo conditions, drug concentrations were
chosen according to actual consensus guidelines for therapeutic
Figure 5. FKBP51 is required for the chronic effects of PAR on behavior and autophagic pathways. Wild-type and 51KO mice were
subjected to CSDS and subsequent chronic PAR treatment resulting in eight experimental groups (n=8–12 per group) that were analyzed for
behavior and autophagy marker protein levels. When the three-way ANOVA indicated an interaction effect (p,0.1), genotype-dependent stress and
treatment effects were isolated by normalizing the data to either unstressed controls or vehicle treatment. (A) General locomotion in the open-field
arena was independent of genotype, condition, or treatment of the mice. (B–D) Deletion of FKBP51 abolished the reaction to CSDS and to chronic
PAR treatment in the social avoidance test. (E–H) Deletion of FKBP51 significantly reduced the effect of chronic PAR treatment in the FST. (I–R)
Deletion of FKBP51 abolished the effects of chronic PAR treatment on the autophagy pathway markers Beclin1, Atg12, pAkt, and LC3B-II/I. Protein
parameters were analyzed in hippocampal brain extracts. Asterisks indicate significant result for planned contrast test for main genotype effect (#),
main treatment effect ($), or main condition effect (+): *p,0.05; **p,0.01. a.u., arbitrary units; SI zone, social interaction zone; WT, wild type.
doi:10.1371/journal.pmed.1001755.g005
Figure 6. Correlation of FKBP51 with autophagy pathway
components in human PBMCs. Protein levels of FKBP51 and Beclin1
(A), pAktS473/Akt (B), LC3B-II/I (C), and Atg12 (D) in PBMCs from healthy
men (n=21). Each dot represents the levels of FKBP51 and the
respective protein in the PBMCs from one individual. Average
expression levels were set to 1.
doi:10.1371/journal.pmed.1001755.g006
Figure 7. Effects of dexamethasone and of antidepressants on
autophagic pathway components in human PBMCs correlate
with FKBP51. (A and B) PBMCs were collected from healthy subjects
(n= 14) before and 6 h after the intake of 1.5 mg of DEX, and proteins
were analyzed. Each dot represents the DEX-induced change in FKBP51
and the expression change of the respective protein (Beclin 1 [A] and
pAktS473 [B]) in the PBMCs of one individual. (C–F) Levels of FKBP51 and
Beclin1 (C), pAktS473 (D), LC3B-II/I (E), and Atg12 (F) in PBMCs from
healthy men (n=21) cultivated ex vivo and treated with PAR (0.365 mM,
48 h). Plots depict protein changes upon treatment with antidepressant
compared to vehicle-treated cells in correlation to FKBP51. Each dot
represents the level of FKBP51 and the expression change of the
respective protein in the PBMCs from one individual.
doi:10.1371/journal.pmed.1001755.g007
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drug monitoring in psychiatry [49]. The extent of dephosphory-
lation of pAktS473, change of LC3B-II/I ratio, and change in levels
of Beclin1 and Atg12 in response to antidepressants correlated
with the expression level of FKBP51 (Figures 7C–7F, S12G, and
S12H; Pearson correlation coefficient for PAR in the case of
Beclin 1, r=0.703, p=0.002; LC3B-II/I, r=0.626, p=0.009;
pAktS473, r=20.467, p=0.068; and Atg12, r=0.665, p=0.005).
Higher expression of FKBP51 was associated with antidepressant-
induced dephosphorylation of pAktS473, and lower expression of
FKBP51 was associated with antidepressant-enhanced pAktS473.
With increasing FKBP51 levels, a gradual shift from slightly
inhibitory to stimulatory effects of antidepressants on Beclin1
expression was observed. Atg12 expression was not significantly
changed by AMI or FLX. Taken together, FKBP51 is required for
the effects of antidepressants and of DEX on autophagic pathways
in humans.
Figure 8. Correlation of the expression of FKBP51, pAkt, and Beclin1 with clinical antidepressant response, and of the autophagic
markers Beclin1, pAkt, and LC3B-II/I with FKBP51. Beclin1, FKBP51, LC3B-II/I, and pAktS473/Akt levels were determined in PBMCs from
inpatients with depression at admission (n=51). (A–C) Expression values of Beclin1 (A), pAktS473/Akt (B), and FKPP51 (C) are correlated with the
response to antidepressant (AD) treatment expressed as percent change in total score on the 21-item HDRS between admission and after 6 wk of
treatment. (D–F) Expression values of the autophagy pathway markers Beclin1 (D), pAktS473/Akt (E), and LC3B-II/I (F) are correlated with the
expression levels of FKBP51.
doi:10.1371/journal.pmed.1001755.g008
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Clinical Improvement of Patients with Depression Is
Predicted by Their Levels of Beclin1 and FKBP51 at
Hospital Admission
To further evaluate the clinical relevance of our findings, we
determined the expression levels of Beclin1, FKBP51, and
pAktS473 in PBMCs from inpatients (for demographic and clinical
parameters see Methods and Ttables 1 and 2) with a current
depressive episode at admission and compared them with the
clinical treatment response. The clinical response after 6 wk of
treatment showed statistically significant positive correlations with
the levels of Beclin1 (Pearson correlation coefficient r=0.521,
p=0.002) and FKBP51 (Pearson correlation coefficient
r=0.6311, p,0.0001), and a negative correlation with pAktS473
(Pearson correlation coefficient r=20.515, p=0.003) (Figure 8A–
8C). The protein analyses in the PBMCs from patients with
depression also confirmed the correlation between the levels of
autophagy markers and the expression levels of FKBP51
(Figure 8D–8F).
Reactivity of Beclin1 and pAkt of Patient-Derived PBMCs
to Antidepressant Treatment Ex Vivo Predicts Clinical
Improvement
PBMCs were also collected from inpatients at admission,
cultivated, and treated with AMI, FLX, or PAR ex vivo for
48 h. We observed a correlation between therapeutic outcome and
the increase of Beclin1 levels in treated PBMCs for all three
antidepressants (Pearson correlation coefficient in the case of PAR,
r=0.569, p=0.004; AMI, r=0.572, p=0.003; FLX, r=0.454,
p=0.024) (Figure 9A–9C). There was a significant negative
correlation between therapeutic outcome and the change of
pAktS473 upon treatment with AMI (Pearson correlation coeffi-
cient r=20.416, p=0.006) or PAR (Pearson correlation coeffi-
cient r=20.355, p=0.021) (no correlation for FLX; Figure 9D–
9F). Therapeutic outcome also significantly correlated with the
induction of LC3B-II/I in the case of treatment with PAR
(Pearson correlation coefficient r=0.453, p=0.020), but not in the
case of treatment with AMI or FLX (Figure 9G–9I). Thus, the
levels of FKBP51 and Beclin1 at admission, as well as the response
to antidepressant treatment in PBMCs, correlate with therapeutic
outcome.
Discussion
In this study, we revealed a novel function of FKBP51 in
directing autophagic processes. Further, FKBP51 is required for
the effects of both acute and chronic antidepressant treatment on
behavior and on autophagic pathways in mice, and for the effects
of antidepressants on autophagy in cells. In humans, treatment
response in patients could be predicted by the expression of
FKBP51, phosphorylated Akt, and Beclin1 in lymphocytes, and in
particular by the response of autophagic markers to antidepressant
treatment of lymphocytes cultivated ex vivo.
FKBP51 was originally selected as a candidate for genetic
analyses in depression and antidepressant responsiveness [8]
because it is involved in the regulation of the glucocorticoid
receptor [7], and thereby the stress hormone axis [61]. Our study
brings novel FKBP51-directed pathways to the fore (Figure 10),
and establishes the importance of FKBP51 in antidepressant
action at the molecular, cellular, and organismic level. It also
Figure 9. Correlation of clinical antidepressant response with the effects of antidepressants in PBMCs ex vivo. PBMCs from inpatients
with depression were cultivated ex vivo and treated with PAR (0.365 mM), FLX (1,695 nM), or AMI (888 nM) for 48 h. The antidepressant-induced
changes in expression of Beclin1 (A–C), pAktS473/Akt (D–F), and LC3B-II/I (G–I) are correlated with the clinical response to antidepressant (AD)
treatment expressed as percent change in total score on the 21-item HDRS between admission and after 6 wk of treatment. The collected PBMCs
were not always sufficient to run all conditions or analyze all proteins: (A, B, D, and E): n= 51; (C): n= 43; (F): n= 42; (G): n= 30; (H): n=31, (I): n=27.
doi:10.1371/journal.pmed.1001755.g009
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identifies a potential molecular mechanism for the previously
suggested [8] positive correlation between FKBP51 expression and
antidepressant treatment response.
The impact of FKBP51 on autophagy established in this study
significantly expands the range of actions of this versatile protein to
be considered relevant for antidepressant action. Our protein
interaction analyses support the model (Figure 10) that FKBP51,
as a scaffolding protein, recruits Akt to Beclin1; since FKBP51 also
binds to PHLPP [53], inactive Akt is recruited to Beclin1. This
results in decreased phosphorylation of Beclin1, thereby shifting
Beclin1’s action to trigger autophagy [19]. FKBP51-mediated
increase in overall Beclin1 levels constitutes a further route by
which FKBP51 facilitates autophagy.
The regulation of FKBP51 by glucocorticoids [3,59] potentially
links all the molecular actions of FKBP51 to stress. Our data
provide strong evidence that up-regulation of FKBP51 mediates
DEX-induced autophagy and dephosphorylation of pAktS473 [60].
Akt, in turn, has been reported previously as a target of
antidepressant action, and both positive and negative changes in
pAktS473 levels have been found for different antidepressants in
various cellular systems [55,56,62,63]. Treatment duration and
other factors may account for the divergent results. Based on our
findings, we propose that FKBP51 expression status determines
whether and how antidepressants alter pAktS473. In general,
pAktS473 is under multifactorial control [64] that could be the basis
for both inhibitory and FKBP51-dependent stimulatory actions of
antidepressants.
In light of the still incompletely understood molecular mech-
anism by which antidepressants act, our results highlight an
FKBP51-dependent intracellular molecular mechanism of antide-
pressant effects that might complement the known actions on
monoaminergic neurotransmitter systems [65]. Nevertheless, given
the complexity of the disease and the plethora of reported
molecular effects of antidepressants, it is unlikely that all
antidepressants, current or future, will depend on FKBP51 or
any other single protein. Similarly, some antidepressants may not
engage the autophagic pathway, such as the newly suggested fast-
acting antidepressants ketamine and scopolamine [57,58], which
did not increase Beclin1 levels.
Autophagy is considered a fundamental process ensuring the
functional integrity and fitness of cells and tissues [17]. Recently, a
link has been discovered from autophagy to neurotransmission
[66], which likely modulates neuronal network dynamics and,
ultimately, behavior [67]. Thus, it is possible that both
neurotransmission and general cell homeostasis are ramifications
of FKBP51-governed autophagy pathways underlying the here
described FKBP51 dependency of PAR’s effect on body weight
gain, stress-coping, and social behavior, and the FKBP51-
dependency of clinical antidepressant response.
Consistent with previous reports [5,6], we found no changes in
depression-like behavior in FKBP51-deleted (51KO) mice under
basal conditions. In partial contrast to these results in young mice
(3–5 mo of age), older 51KO mice (17–20 mo of age) exhibited
shorter immobility times in the behavioral despair tests forced
swimming and tail suspension [68]. Whether this reflects an age-
dependent adaptation of the animals to FKBP51 deletion or
whether FKBP51 may exert age-dependent effects will be
interesting to investigate. It is worth noting that FKBP51
expression has been shown to increase with age [69].
One of the limitations of the study is the use of only men for the
association study of FKBP51 and markers of autophagy and of
FKBP51-dependent antidepressant effects in PBMCs. However, the
pathway connections and FKBP51 dependency were confirmed in
the cohort of patients with depression that comprised women and
men. Similarly, only male mice were analyzed in the animal
behavior experiments. Further, it should be noted that the clinical
sample used for the protein analyses is small (n=51). In addition,
there is a general consensus that animal models for depression or
antidepressant action do not fully replicate the situation in humans,
but only model certain endophenotypes. Finally, it will be
interesting to test in future studies whether the use of other
autophagy-triggering substances elicits antidepressant-like effects,
preferably substances that increase the levels of Beclin1.
While genetic studies of complex diseases, including studies of
respective drug actions, have significantly benefitted from the
advanced technologies of genome-wide genotyping, the necessity
of complementary approaches, such as molecular pathways and
network analyses, to move from genomic localization to mecha-
nistic insight has come into focus only recently [70]. Overall, our
finding of FKBP51-dependent antidepressants’ effects on intracel-
lular pathways, brain function, and behavior strengthens the
relevance of the genetic association of FKBP51 with antidepres-
sant response and, furthermore, substantiates the need for more
targeted genetic studies. In addition, our results suggest consider-
ing autophagy-initiating mechanisms as a pharmacological target
to improve the treatment of depression, as has already been
discussed for other diseases [20]. Finally, our data call for
replication in an independent sample to validate the usefulness
of the protein expression status of autophagic factors—as well as
Figure 10. Model of FKBP51’s impact on Beclin1 and autoph-
agy pathways. FKBP51 interacts with PHLPP, Akt, and Beclin1. Since
PHLPP dephosphorylates Akt (S473 in Akt1), inactive Akt is recruited to
Beclin1. This results in lower phosphorylation of Beclin1 and, thus, the
induction of autophagic pathways [19]. Autophagic pathways, and
thereby also FKBP51, are linked to cell homeostasis and to synaptic
(syn.) function [66] as a physiological correlate of behavior [71].
Antidepressants act on the same pathways in an FKBP51-dependent
manner and change FKBP51 protein interactions; this could form the
basis for the FKBP51 dependency of antidepressant effects in cells,
animals, and humans.
doi:10.1371/journal.pmed.1001755.g010
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the response of these factors to antidepressant treatment of ex vivo
cultivated lymphocytes—as novel biomarkers predicting antide-
pressant efficacy in patients with depression.
Supporting Information
Figure S1 Representative Western blots for Figure 1C–
1G (A) and Figure 1H–1K (B).
(TIF)
Figure S2 Functional interaction of FKBP51 with Be-
clin1, Akt, and PHLPP. HEK cells were transiently transfected
with vector control or a plasmid expressing FKBP51. (A) Numbers
indicate the effect of FKBP51 expression on the levels of Beclin1
and on the phosphorylation status of AktS473 and AktT308,
corresponding to Figure 2B. Three independent experiments were
performed. (B) Representative Western blots of Beclin1 immuno-
precipitations from transfected cells and analysis of pBe-
clin1S234,S295 and co-precipitating pAktS473/Akt are displayed
(corresponding to Figure 2C). The antibodies directed against
phosphorylated Beclin1 worked only after immunoprecipitation
[19]. The table summarizes the results of three independent CoIPs
and Western blot detections. In the case of Akt and pAktS473,
numbers indicate relative intensities of interaction with Beclin1
(intensity of vector control was set to 1), including p-values of
interaction differences. In the case of pBeclin1S234,S295, numbers
indicate the fold change in the presence or absence of ectopic
FKBP51 (vector control set to 1), including p-values.
(TIF)
Figure S3 Effect of FKBP51 on autophagic flux. (A)
Titration of bafilomycin A1. Rat cortical astrocytes were incubated
with increasing concentrations of bafilomycin A1 as indicated for
2 h. Levels of LC3B-I, LC3B-II, and Actin were determined in
protein extracts by Western blotting. (B) FKBP51 enhances
autophagic flux. Rat cortical astrocytes were transfected with
FKBP51 or vector control and treated with bafilomycin A1 as
indicated; the levels of LC3B-II/Actin were determined, yielding
results similar to the LC3B-II/I ratio (Figure 2F). Representative
Western blot corresponding to Figure 2F also presented. *p,0.05.
See Table S1 for all statistical parameters.
(TIF)
Figure S4 Concentrations of amitriptyline and paroxe-
tine needed to elicit markers of autophagy. Primary cortical
astrocytes were treated with PAR (A) or AMI (B) at the concentrations
indicated for 72 h. Protein levels were determined for pAktS473/Akt,
Beclin1, Atg12, and LC3B-II/I. Representative Western blots are
shown. Graphs display the relative abundance measured in three
independent experiments. *p,0.05; **p,0.01; ***p,0.001.
(TIF)
Figure S5 Convergent effects of FKBP51 and antide-
pressants on protein interactions and pAktS473 in cells.
(A) The interaction of FKBP51 with Beclin1 and Akt was analyzed
by Western blotting after CoIP from HEK cells cultivated in the
presence or absence of AMI or FLX (10 mM each) for 72 h. Table
indicates changes in protein interaction relative to vehicle
treatment and includes also PAR (corresponding to Figure 3A).
(B and C) Cortical astrocytes were transfected with an FKBP51
expression or control plasmid and treated with PAR, AMI, or
FLX (10 mM each) for 72 h; levels of pAktS473/Akt were
determined by Western blotting (representative blot in [B], also
corresponding to Figure 3B). Protein levels in control-transfected
untreated cells were set to 1 (dashed line). (D–F) Wild-type MEFs,
51KO MEFs, and 51KO MEFs transfected with an FKBP51-
expressing plasmid were treated AMI, FLX, or PAR (10 mM each)
for 72 h, and the pAktS473/Akt and LC3B-II/I ratios were
determined by Western blot (representative blot in [D], corre-
sponding to Figure 3C and 3D). Protein levels in wild-type
untreated cells were set to 1 (dashed line). *p,0.05. See Table S1
for all statistical parameters.
(TIF)
Figure S6 Convergent effects of FKBP51 and antide-
pressants on LC3B-II/I, Beclin1, and Atg12 in cells. (A
and B) Wild-type MEFs, Akt1/2KOMEFs, and Akt1/2KOMEFs
transfected with Akt1- and Akt2-expressing plasmids were treated
with AMI, FLX, or PAR (10 mM each) for 72 h. The ratio of
LC3B-II/I was determined by Western blot (representative
example in [B]). LC3B-II/I in the respective untreated cells was
set to 1 (dashed line). (C and D) primary rat cortical astrocytes
were transfected with a vector expressing GFP-LC3B, in
combination with an FKBP51-expressing vector or cloning vector,
and treated with AMI or FLX (10 mM each) for 72 h. The number
of GFP-LC3B-positive puncta was determined per cell (C). 15–25
randomly selected cells were evaluated for each condition
(representative fluorescence images in [D]). (E) Cortical astrocytes
were transfected with an FKBP51 expression or control plasmid,
and treated with AMI, FLX, or PAR (10 mM each) for 72 h; the
levels of Beclin1, LC3B-II/I, and Atg12 were determined by
Western blotting (PAR data displayed in Figure 3G–3I; represen-
tative blot in Figure S5B). Protein levels in vector-transfected
untreated cells were set to 1 (dashed lines). *p,0.05; **p,0.01;
***p,0.001. See Table S1 for all statistical parameters.
(TIF)
Figure S7 Antidepressants elicit autophagic markers
after 45 min in primary astrocytes. Primary cortical
astrocytes were incubated for 45 min with vehicle or with
10 mM of the antidepressant indicated. Protein levels of the
indicated autophagy marker proteins were determined by Western
blotting. Representative Western blot is provided. Protein levels in
untreated cells were set to 1 (dashed lines). *p,0.05; **p,0.01;
***p,0.001. See Table S1 for all statistical parameters.
(TIF)
Figure S8 Antidepressants enhance autophagic flux. Rat
cortical astrocytes were incubated with the drugs as indicated for
2 h, and the levels of LC3B-I, LC3B-II, and Actin were
determined in protein extracts by Western blotting. The graphs
display the ratios of LC3B-II/I and of LC3B-II/Actin from three
independent experiments. The LC3B-II/I ratio corresponding to
the LC3B-II/Actin ratio of (C) is displayed in Figure 3J. The levels
in the presence of bafilomycin A1 were set to 1 (dashed lines). *p,
0.05; **p,0.01; ***p,0.001. See Table S1 for all statistical
parameters. BafA1, bafilomycin A1; RAP, rapamycin.
(TIF)
Figure S9 Paroxetine and FKBP51 enhance Beclin1 in
primary neuronal cells. Primary cortical neurons were
transfected with vector or FKBP51-expressing plasmid and treated
with PAR (10 mM) or vehicle for 72 h as indicated. The levels of
Beclin1 and Actin were determined by Western blotting. *p,0.05;
**p,0.01. See Table S1 for all statistical parameters.
(TIF)
Figure S10 Autophagic markers are largely unaffected
by haloperidol, ketamine, and scopolamine. (A) C57BL/6
mice (n=6) were intraperitoneally injected with haloperidol
(0.2 mg/kg) or saline and sacrificed 45 min later for preparation
of brain extracts. (B) Rat cortical astrocytes were treated with
ketamine (30 mM or 100 mM, left), scopolamine (1 mM or 3 mM,
right), or vehicle for 45 min, and protein extracts were prepared.
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For (A and B), protein levels of autophagy markers were
determined by Western blotting (representative blots are provid-
ed). *p,0.05; **p,0.01. See Table S1 for all statistical
parameters. Ket, ketamine; SCO, scopolamine.
(TIF)
Figure S11 FKBP51 shapes the neuroendocrine effects
of chronic stress and chronic paroxetine treatment. Time
course is provided in Figure 4A. When the three-way ANOVA
indicated an interaction effect (p,0.1), genotype-dependent stress
and treatment effects were isolated by normalizing the data to
either unstressed controls or vehicle treatment. (A) CSDS resulted
in significantly increased basal corticosterone levels in wild-type
mice, but not in 51KO mice (p,0.05). (B) Basal corticosterone
levels assessed 3 wk after the stressor were significantly lower in
51KO mice. (C) Basal corticosterone levels of 51KO mice were
less affected by the long-lasting effects of CSDS. (D) PAR
decreased basal corticosterone, especially in 51KO mice. (E and
F) Circulating corticosterone was significantly decreased in 51KO
mice in response to an acute stressor, as well as after a 90-min
recovery period Asterisks indicate significant result for planned
contrast test for main genotype effect (#), main treatment effect
($), or main condition effect (+): *p,0.05. See Table S1 for all
statistical parameters.
(TIF)
Figure S12 FKBP51 dependendency of autophagy path-
way components in human PBMCs and of the effects of
dexamethasone and antidepressants in primary astro-
cytes and in human PBMCs. (A) Protein extracts from
PBMCs of healthy individuals were analyzed for expression of
FKBP51 and components of the autophagy pathway. Represen-
tative Western blot corresponding to Figure 6 is shown. (B)
PBMCs were collected from healthy individuals (n=14) before
and 6 h after the intake of 1.5 mg of DEX, and proteins were
analyzed. Representative Western blot corresponding to Fig-
ure 7A and 7B is shown. (C–F) Primary astrocytes from FKBP51+/
+ and 51KO mice were treated with vehicle or DEX (10 mM for
6 h), and protein levels were determined by Western blot
(representative blot in [F]). (G) Representative Western blot of
extracts from antidepressant-treated PBMCs (corresponding to
Figure 7C–7F and table in [H]). (H) Summary of the correlations
of the effects of antidepressants on autophagic markers with the
expression of FKBP51 in PBMCs from healthy individuals.
(TIF)
Table S1 Details of the results of the ANOVA analyses.
(PDF)
Table S2 Details of the results of the regression
analyses.
(PDF)
Text S1 STROBE statement.
(DOCX)
Text S2 ARRIVE guidelines checklist.
(DOC)
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Editors’ Summary
Background. Everyone feels miserable sometimes, but
about one in six people will have an episode of clinical
depression during their lifetime. For people who are clinically
depressed, overwhelming feelings of sadness, anxiety, and
hopelessness can last for months or years. Affected
individuals lose interest in activities they used to enjoy, they
sometimes have physical symptoms such as disturbed sleep,
and they may contemplate suicide. Clinicians diagnose
depression and determine its severity using questionnaires
(‘‘depression rating scales’’) that explore the patient’s
feelings and symptoms. Mild depression is often treated
with talking therapies (psychotherapy) such as cognitive
behavioral therapy, which helps people change negative
ways of thinking. For more severe depression, patients are
also usually prescribed an antidepressant, most commonly a
‘‘selective serotonin reuptake inhibitor’’ such as paroxetine
or a tricyclic antidepressant such as amitriptyline.
Why Was This Study Done? Unfortunately, antidepres-
sants don’t work for more than half of patients. Moreover,
because it is unclear how antidepressants work, it is not
possible to predict which patients will respond to which
antidepressants. Thus, matching patient to drug can be a
lengthy, sometimes unsuccessful, process. Here, the re-
searchers use several approaches to test the hypothesis that
a protein called FK506 binding protein 51 (FKBP51) is
involved in the actions of antidepressants and to investigate
whether the ability of both FKBP51 and antidepressants to
regulate a process called autophagy underlies the impact of
FKBP51 on antidepressant responses. FKBP51 is a regulator
of stress physiology, which is connected to the development
and treatment of depression; genetic studies have suggested
a link between FKBP51 expression and the antidepressant
response rate. Some antidepressants are known to alter the
initial steps in the autophagy pathway, a multistep process
that maintains the integrity of cells through regulated
degradation and recycling of cellular components; however,
the potential synergistic role of FKBP51 and antidepressants
in regulating pathways of autophagy are unknown.
What Did the Researchers Do and Find? The researchers
first treated wild-type mice and FKBP51 knockout mice
(genetically altered animals that make no FKBP51) with an
acute dose of antidepressant and compared their behavior in
a forced swim test, an assay that measures the action of
antidepressants in mice by determining how long the mice
struggle or float inertly when placed in deep water. As
expected, acute antidepressant treatment increased the time
that wild-type mice spent struggling. However, this effect of
antidepressant treatment was greatly attenuated in the
FKBP51 knockout mice. Moreover, the levels of several
autophagy markers increased in the brains of wild-type mice
following antidepressant treatment but not in the brains of
FKBP51 knockout mice. Next, using ‘‘chronic social defeat
stress’’ to model the ‘‘endophenotype’’ of depression (a
combination of physiological, hormonal, and behavioral
traits seen in people with depression) in mice, the
researchers showed that the stress response and the effect
of chronic antidepressants on behavior and on autophagic
markers all depend on FKBP51. Using cell-based assays, the
researchers showed that antidepressants and FKBP51 had
synergistic (interactive) effects on the autophagic pathway
and that, in human blood cells, FKBP51 levels correlated with
the potential of antidepressants to induce autophagic
pathways. Finally, the researchers report that the clinical
response to antidepressant treatment in 51 patients with
depression was associated with the response of autophagic
markers in their peripheral blood lymphocytes to antide-
pressant treatment in test tubes, and that the expression
levels of FKBP51 and autophagy markers in patient lympho-
cytes at admission were associated with subsequent clinical
responses to antidepressants.
What Do These Findings Mean? These findings suggest
that the protein FKBP51 is required for the effects of both
acute and chronic treatment with some antidepressants on
behavior and on autophagic pathways in mice. These
findings also reveal an association between antidepressant
treatment responses in patients and both the expression
levels of FKBP51 and autophagy markers in lymphocytes at
admission and the response of autophagic markers to
antidepressant treatment in patient lymphocytes. The
accuracy of these findings is limited by the small number
of clinical samples available for analysis, by the use of only
male mice in the animal experiments, and by the inability of
animal models of depression to fully replicate the human
condition. Nevertheless, these findings identify the early
stages of autophagy as potential targets for the develop-
ment of new antidepressants and identify several potential
biomarkers that might, after further clinical validation, help
clinicians predict antidepressant efficacy in patients with
depression.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001755.
N The US National Institute of Mental Health provides
information on all aspects of depression (in English and
Spanish), including information on antidepressants
N The UK National Health Service Choices website provides
detailed information about depression and about
antidepressants; it also provides personal stories about
depression
N The UK charity Mind provides information on depression,
including some personal stories about depression
N More personal stories about depression are available
from healthtalk.org
N MedlinePlus provides links to other resources about
depression
N Wikipedia has a page on autophagy (note that Wikipedia
is a free online encyclopedia that anyone can edit;
available in several languages)
N The patients included in this study were all enrolled in
the Munich Antidepressant Response Signature project,
which aims to identify gene variants and biomarkers that
predict treatment outcomes with antidepressants
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